We studied prospectively 49 patients being treated in an intensive care unit with aminoglycosides for gram-negative sepsis. Pharmacokinetic data were calculatedfrom three post-dose serum levels using a one-compartment model. Doses required to achieve peak levels between 5 and 10 mgll with trough levels approximately 1.0 mg 1I ranged between 2 and 12 mglkg per day (mean dose 7 mglkg per day). During therapy 60% of the patients had a change in their apparent volume of distribution (Vd) of greater than 20%. These patients were likely to have confirmed infection and to be febrile at the start of treatment. Two to three weeks after discharge ten patients were restudied after a single dose of aminoglycoside. There was a reduction in mean Vdfram 0.24 to 0.18 IIkg (P < 0.02). Critically ill patients have significantly larger volumes of distribution and may require larger doses per kilogram of body weight of aminoglycoside to achieve therapeutic concentrations. Due to considerable variation in kinetic parameters, the use of standard doses or dosing nomograms is not recommeded.
The aminoglycoside antibiotics continue to be chosen as first-line therapy for the treatment of serious gram-negative infections. There is evidence that strongly suggests that achievement of therapeutic serum levels in the first twenty-four hours of therapy in the seriously ill results in improved survival. 1·3 A study of general hospital patients demonstrated large interpatient variability in volume of distribution (Vd), clearance (Cl) and half-life (t l 12) after a test dose of an aminoglycoside antibiotic. 4 There has been little information published regarding the pharmacokinetics of the aminoglycosides in the critically ill. It has been suggested that underestimation of the Vd contributes to frequent sub-therapeutic dosing in patients in the intensive care unit (lCU).5.6 Given the need for therapeutic serum concentrations to be achieved as quickly as possible while using a group of drugs well known for their potential toxicity, we thought that a greater understanding of the pharmacokinetic changes likely to be seen in the critically ill might lead to more effective aminoglycoside therapy. We therefore studied the kinetics of aminoglycosides in the critically ill, the changes in kinetics during continued therapy and, in a sub-group ofpost-ICU patients, their kinetics after discharge from hospital.
MA TERIAL AND METHODS

On admission to ICU
Patients studied were those admitted to a general ICV of a teaching hospital who were receiving an aminoglycoside antibiotic (gentamicin, tobramycin, amikacin) or who subsequently received an aminoglycoside Anaesthesia and Intensire Care. }'ol. 16, No. 4. Nu\·ember. 1988 antibiotic while in the ICU. The prescribed aminoglycoside was given as a slow intravenous injection over five minutes. If the patient was already receiving an aminoglycoside, a trough level was taken just before the next dose was due. In all cases a peak level was taken thirty minutes after the completion of the slow injection and a further two samples taken over two estimated halflives. This was usually at two and four hours post-dose. If a diminished creatinine clearance was suspected, the sampling time was extended to 8, 12 or even 24 hours. Blood was also taken for measurement of serum creatinine concentration at two hours post-dose.
During therapy
While patients continued to be treated in the ICU, peak and trough levels were measured every second to third day. Renal function was monitored daily.
post-feu study
Patients who were eventually discharged well from hospital were invited to return two weeks later in order to measure their kinetics while in a 'disease-free' state. A 1.0 mg/kg dose of the same aminoglycoside the patients received in the ICU was again given intravenously over five minutes. Although this was not necessarily the same dose as that given initially in the ICU, there is no evidence that the kinetics of aminoglycosides are dosedependent. Blood samples were taken over two estimated half-lives with the peak level taken at thirty minutes post-dose.
Analysis
All aminoglycoside samples were assayed using a fluorescent polarisation immunoassay with a coefficient of variation of less than 10% for both control samples and inter-batch samples. The lower limit of sensitivity for the assay was 0.2 mg/I. Pharmacokinetic data were derived from a one-compartment kinetic model using multi-infusion kinetics. 7 The serum concentration time data from the postinfusion phase were fitted to a single exponential term using least squares linear regression analysis allowing Vd, Cl and t1f2 to be calculated. Serum creatinine concentration was measured using standard auto-analyser techniques. Student's t test, paired t test and Chi squared test were used for statistical analysis and a value of P < 0.05 was considered to be significant.
Ethical considerations
The study was approved by the Ethics Committees of the Royal Newcastle Hospital and the Mater Misericordiae Hospital, Newcastle.
RESULTS
Over a six-month period, 49 patients received an aminoglycoside antibiotic in an ICU with a total of 54 kinetic profiles being measured (five patients were readmitted to ICU). Sixteen patients subsequently died while 33 were discharged from hospital. Ten patients volunteered to take part in the post-ICU study. Table 1 shows the mean results for t'12, Vd and Cl for the 54 kinetic profiles analysed. Of note is the extreme variability of the results as shown by the almost tenfold difference in the range. The wide variation in results is still obvious even when the patients are divided into groups of normal and abnormal renal !' W function based on serum creatInIne concentration ( Table 2 ). Although t1f2 and Cl are significantly different in these groups there is a large overlap in the range of results.
It was noted that Vd often changed during therapy, much more so than Cl. Although both negative and positive changes were observed, more frequently a fall in Vd occurred. Figure 1 demonstrates the maximum change in Vd from the initial value in the forty patients who had peak and trough levels taken during therapy. Only fifteen (38%) of the patients had a relatively stable Vd showing less than a 20% maximum change. The remaining twenty-five patients (62%) had unstable volumes of distribution with changes ranging from 25% to 207%. We analysed retrospectively the stable and unstable Vd groups in an attempt better to predict which patients might experience large changes in Vd ( Table 3 ). The unstable group were more likely to have a confirmed infection by isolation of a causative organism and to be febrile ( therapy. Despite a clinical impression that the unstable patients tended to be more seriously ill, this was not evident in the results.
After discharge from hospital, ten patients returned two to three weeks later for estimation of their pharmacokinetic parameters while they were apparently healthy. The 'post-ICU group' was a representative sub-group of the original ICU group when sex, weight, age, initial site of infection, tif2, Vd and Cl were compared. None of the ten patients was on diuretics at the time of the study. Table 4 shows the t'12, Vd and Cl of the ten patients during their ICU admission and post-ICU study. There was no statistical difference in t'12 and Cl; however, Vd demonstrated a mean drop of 0.06 IIkg, a greater than 25% change which was highly significant.
DISCUSSION
The results from the 54 ICU kinetic profiles showed marked variation in the three pharmacokinetic parameters; t'12, Vd and Cl. Almost a tenfold variation in the range was observed and it is this variation coupled with the need to attain therapeutic serum concentrations as quickly as possible that poses problems for the intensivist when decisions on dosing have to be made. Numerous dosage schedules and nomograms have been devised to enable the clinician to target the narrow therapeutic window that exists with the aminoglycoside antibiotics. s . lo However, these nomograms are based on the invalid assumption that Vd and Cl are both in the normal range and are stable which often does not hold in the ICU, thereby resulting in either sub-therapeutic or toxic levels. It is the peak level achieved which is thought to have the bactericidal effect, and the peak level attained after a given dose of the drug is dependent on the Vd and not on the Cl or tlf2 because no significant excretion takes place before the peak level is reached. Thus it is the Vd that gains importance when considering a dose designed to achieve a therapeutic level. We noted that the Vd often changed during therapy and because the clinician will usually need to alter the dose when the Vd changes by 20%, it was decided that the group of patients whose Vd changed by greater than 20% would be classed as the 'unstable' group. This group was more likely to be febrile and to have a confirmed infection. In individual cases changes in Vd were associated with correction of hypotension or dehydration, changes in oedema or ascites, or correction of known fluid overload; however, due to the small sample generalised conclusions are not able to be made.
Our results and opinions are in accord with those of Denaro and Ravenscroft l3 who advocated the use of individual pharmacokinetic profiles in severely ill patients. However, their assessments were made only in hospital and were not confined to patients in the ICU.
The frequency of dosing has in the past been made on an estimate of the patient's renal clearance, using serum creatinine as a predictor. It has already been observed in general inpatients that the variation in aminoglycoside clearance is too great even when patients are grouped into those with normal and high serum creatinine concentrations. 4 Our data reinforce this in the ICU environment. The use of the three-point kinetic profile allows the half-life to be calculated accurately for each patient, potentially resulting in an improved therapeutic result.
The restudying of a group of patients who were discharged well from hospital may indicate possible effects of acute illness on the pharmacokinetics of the aminoglycosides. The Vd of critically ill patients falls significantly when they have recovered necessitating larger doses to be given in the ICU. Our mean dose to achieve therapeutic peak and trough concentrations was 7 mg/kg/ day, well above the recommended 3 to 5 mg/kg/day. The range of doses given varied from 2 to 12 mg/kg/day. Absolute doses ranged from 40 mg to 320 mg of gentamicin and tobramycin and dosing intervals varied from every four hours to every 36 hours. Often large doses were given concurrently with a short dosing interval (e.g. 160 mg e\"ery four hours). The reason for the fall in Vd is uncertain, but may parallel movement of a small water-soluble molecule in a situation of generalised altered capillary permeability. Due to the large variation in pharmacokinetic parameters, the use of individualised aminoglycoside therapy is strongly recommended in the critically ill.
